576 search results for “anti-inflammatory drug” in the Staff website
-
Suzanne WenkerFaculty of Science
-
Fouzia Lghoul-Oulad SaidFaculty of Science
-
Aida Naghilouye HidajiFaculty of Science
-
Chenyu WangFaculty of Science
-
Qinhao WuFaculty of Science
-
Hidde van de BeekFaculty of Science
-
Janneke LootensFaculty of Science
-
Jannik RouselFaculty of Science
-
Asina GijasiFaculty of Science
-
Douwe BreimerFaculty of Science
-
Marije OttoFaculty of Science
-
Suruchi NepalFaculty of Science
-
Barbara ScalviniFaculty of Science
-
Menno HoekstraFaculty of Science
-
Jill de MolFaculty of Science
-
Joachim van GuyseFaculty of Science
-
Amy HarmsFaculty of Science
-
Martijn MansonFaculty of Science
-
Mengxu ZhangFaculty of Science
-
Zixuan WangFaculty of Science
-
Sebastian TandarFaculty of Science
-
Eric BangFaculty of Science
-
Chunyuan YinFaculty of Science
-
Zhiyuan TanFaculty of Science
-
Ilze BotFaculty of Science
-
Dimitra EleftheriouFaculty of Science
-
€10.6 million for innovative toolboxes to tackle brain cancer
Researchers at the Universities of Amsterdam (Uva) and Leiden together with the Netherlands Cancer Institute and Oncode Institute have received a €10,6 million ERC Synergy Grant to develop innovative therapeutic approaches to target glioblastoma. This is a deadly primary brain tumour for which no curing…
-
Master student Nicole ter Laak wins third “Dr. Saal van Zwanenberg research price”
Nicole ter Laak (Master student Biopharmaceutical sciences) has won the third price of the “Dr Saal van Zwanenberg research price”. The award ceremony is on 14 November.
-
Selective cannabinoid CB2 receptor activation in Nature Communications
This March, Jara Bouma, Cas van der Horst and Laura Heitman from the Division of Drug Discovery and Safety and Laura de Paus, Richard van den Berg, Anthe Janssen and Mario van der Stelt from the LIC joined forces to determine how some drugs can specifically target the cannabinoid CB2 receptor (CB2R)…
-
Powerful new Leiden 'super antibiotic' may overcome resistance
The prestigious journal Science Translational Medicine has published a study by researchers from the Institute of Biology Leiden (IBL) on a potent new antibiotic that can overcome resistance. ‘The idea was to tweak the original antibiotic and create a next-generation drug’, says Nathaniel Martin, professor…
-
Micha DrukkerFaculty of Science
-
Gerhard BurgerFaculty of Science
-
Dongdong BiFaculty of Science
-
700,000 euros for the fight against aggressive breast cancer
To inhibit proteins that contribute to the growth of aggressive cancer cells, that’s the plan of Professor Bob van de Water and his team. They will receive over 700,000 euros from the KWF Dutch Cancer Society for their research. Researcher Maaike Vreeswijk and pathologist Danielle Cohen are affiliated…
-
Zware metalen hebben slechte reputatie, maar genezen ook kanker
Veel mensen denken dat zware metalen giftig zijn en mens en natuur altijd schade aanbrengen. Dat beeld moet genuanceerd worden, vindt hoogleraar Sylvestre Bonnet.
-
One million euros grant for smart antibiotic combinations – tackling resistant infections and antimicrobial resistance
Optimised antibiotic combinations can combat bacteria more effectively while also slowing the development of resistance. Scientists from five European countries are joining forces to identify such combinations and provide tools for others to do the same. The project is led by Professor Coen van Hasselt…
-
Referral options
If you’re unsure where to refer students to for well-being support, this page should help. It provides an overview of the support available at Leiden University.
-
Obesity and medication: when does bodyweight matter?
How can we best treat infectious diseases in people with obesity? Hospital pharmacist and PhD researcher Koen van Rhee studied how obesity affects blood levels of two commonly used medicines. He also developed a method for pharmaceutical companies to test new drugs on this patient group.
-
More research on side effects: ‘Side effects are not a side issue’
We need to be quicker and better at discovering side effects. In her inaugural lecture, Agnes Kant, Professor by Special Appointment of Innovation of Pharmacovigilance, calls for more research on these adverse effects.
-
Oncode Accelerator funds preclinical development of cancer therapies
Through its Demonstrator Projects, the Dutch Oncode Accelerator consortium provides grants for preclinical cancer therapy development. The first call for these projects is open until September 2025.
-
Pharma-NL application submitted to National Growth Fund
The Ministry of Health, Welfare and Sport (VWS) submitted Pharma-NL to the R&D program of the National Growth Fund, a 20 billion euro program of the Dutch government that intends to create long-term economic growth in The Netherlands.
-
Leiden researchers join forces against tuberculosis
About one and a half million people worldwide die each year from tuberculosis. For thirty years, therapy with antibiotics has been the same, while it takes far too long and can lead to resistant pathogens. Leiden researchers from four institutes are now joining forces to develop more effective and efficient…
-
Sebastian Pomplun receives ERC Proof of Concept grant for MYSTIC, to advance an innovative cancer treatment idea
Sebastian Pomplun from the Leiden Academic Centre for Drug Research has recently received an ERC Proof of Concept grant for his ambitious MYSTIC project. This initiative is set to transform cancer treatment by advancing the development of HeloMYC, a pioneering therapeutic candidate designed to target…
-
Discover the Oncode Accelerator research funds for cancer therapies
Research
-
Fighting gliobastoma brain tumours with two grants
Few researchers see potential in research on glioblastoma, an incurable brain tumour. Alexander Kros brought together colleagues who are up to the challenge. European research funder ERC recently made 10.6 million euros available, a year earlier NWO provided 3 million euros. ‘In six years, we certainly…
-
Salvador Santino Regilme awarded fellowship at NIAS
Salvador Santino Regilme has been selected for a fellowship at the Netherlands Institute for Advanced Study (NIAS) in Amsterdam. From September 2022, he will spend 5 months at NIAS working on his research project titled 'The Normative Order of the Global War on Drugs'.
-
Joke Bouwstra is the first woman to receive the Dr Saal van Zwanenberg Honorary Prize: 'Wonderful to be in a line of distinguished scientists'
Emeritus professor Joke Bouwstra (LACDR) will receive this year's Dr Saal van Zwanenberg Ereprijs: a tribute to her years of fundamental research on the skin and the transport of drugs through the skin. This is the first time the prize has gone to a woman.
-
No higher risk of miscarriage after COVID-19
LUMC research has shown that women who previously had a miscarriage due to COVID-19 are not at increased risk of having another miscarriage or a stillbirth. Nor are preventive drugs needed during the pregnancy.
-
Professor and Knight: Joke Bouwstra Receives Royal Honor
A memorable farewell symposium and a royal distinction: Professor Joke Bouwstra could not have completed her career at Leiden with more pleasure. On Friday, 14 June, she received a Royal Honor from Leiden Mayor Peter van der Velden, who appointed Bouwstra as a Knight in the Order of the Dutch Lion for…
-
Let the robot lend a hand in the pharmacy (it’s more sustainable too)
Can a robot help prepare cancer medication in a hospital pharmacy? That’s what hospital pharmacist Tjerk Geersing investigated in his PhD research. He compared manual and automated preparations in terms of quality, efficiency, and safety. He graduated on 19 March.